Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 12:45:02 16/06/2025 pm IST			5-day change	1st Jan Change
1,481.00 ^DKK	0.00%		+2.46%	-0.77%

09:50am	Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	MT
09/06	Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM

GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded

Published on 08/11/2023 at 19:14, updated on 08/11/2023 at 19:52

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	09:50am	MT
Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM	09/06
AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	09/06	MT
GENMAB : Beaten up share price offers an opportunity	06/06
Genmab's Rina-S shows promising efficacy in difficult-to-treat uterine cancer	03/06	FW
Sector Update: Health Care Stocks End Higher Late Afternoon	03/06	MT
Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan	03/06	MT
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	03/06	CI
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	30/05	FW
RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating	29/05	MT
Deutsche Bank lowers target price for Genmab to DKK 1,750 (1,900), reiterates buy recommendation	23/05	FW
Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation - BN	23/05	FW
Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association Congress	14/05	CI
UBS lowers target price for Genmab to DKK 2,600 (2,700), reiterates buy recommendation	12/05	FW
GENMAB : Mixed Q1; guidance maintained	10/05
Nordea Bank Upgrades Genmab to Buy	09/05	MT
Nykredit lowers target price for Genmab to DKK 1,750 (2,000), reiterates buy recommendation - BN	09/05	FW
Nordea raises Genmab to buy (hold), target price SEK 2,009	09/05	FW
Goldman Sachs raises target price for Genmab to DKK 1,785 (1,764), reiterates neutral rating - BN	09/05	FW
Carnegie raises target price for Genmab to DKK 2,288 (2,263), reiterates buy recommendation - BN	09/05	FW
Cowen lowers target price for Genmab to DKK 1,360 (1,431), reiterates hold rating - BN	09/05	FW
Genmab A/S, Q1 2025 Earnings Call, May 08, 2025	08/05
Genmab Q1 Earnings, Revenue Increase	08/05	MT
Genmab A/S Maintains Earnings Guidance for the Year 2025	08/05	CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	08/05	CI

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,638

Sector

Biotechnology & Medical Research

Calendar

17/06 - International Malignant Lymphoma Conference

More about the company